Inclusion Criteria:

- Patients with chronic myeloid leukemia;

- Age: 18-65 years,gender:both.

- Weight: standard weight ± 20% within, and avoid weight disparity is too large;

- No previous radiation therapy, chemotherapy, or surgery within 1 weeks before
treatment with imatinib;

- Performance status 0 to 3 (WHO scale); Life expectancy greater than 3 months;

- No other malignancy;

- Adequate hepatic, renal, and bone marrow function
(WBC≥3.0×109/L，ANC≥1.5×109/L，PLT≥80×109/L. Serum bilirubin≤1.5×the institutional
upper limit of normal, ALT、ALP≤2.5×the institutional upper limit of normal,
creatinine≤1.5×the institutional upper limit of normal);

- Ability to understand objectives of the study, the study procedure, the
pharmacological properties of the drug and possible adverse reactions and the
willingness to sign a written informed consent.

Exclusion Criteria:

- Suffering from heart, liver, kidney disease or severe acute and chronic
gastrointestinal diseases;

- Pregnant or lactating women and be sensitive to drug;

- Subjects are thought unsuitable for the study by investigators;

- Inability to comply with protocol or study procedures in the opinion of the
investigator;

- Attending other clinical trials or attended other clinical trials 3 months ago.